Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hematology: The case against rituximab maintenance.

× No keyword cloud information.

10 in total

1. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

Authors: Roswitha Forstpointner; Michael Unterhalt; Martin Dreyling; Hans-Peter Böck; Roland Repp; Hannes Wandt; Christiane Pott; John F Seymour; Bernd Metzner; Annette Hänel; Tanja Lehmann; Frank Hartmann; Hermann Einsele; Wolfgang Hiddemann
Journal: Blood Date: 2006-08-31 Impact factor: 22.113

2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Authors: Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning
Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544

3. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Authors: Marinus H J van Oers; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Randy D Gascoyne; Andrew Jack; Mars Van't Veer; Andrej Vranovsky; Harald Holte; Martine van Glabbeke; Ivana Teodorovic; Cynthia Rozewicz; Anton Hagenbeek
Journal: Blood Date: 2006-07-27 Impact factor: 22.113

4. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

Authors: Marinus H J van Oers; Martine Van Glabbeke; Livia Giurgea; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Mars van t Veer; Andrej Vranovsky; Harald Holte; Anton Hagenbeek
Journal: J Clin Oncol Date: 2010-05-03 Impact factor: 44.544

5. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.

Authors: John D Hainsworth; Sharlene Litchy; Don W Shaffer; Van L Lackey; Manuel Grimaldi; F Anthony Greco
Journal: J Clin Oncol Date: 2005-01-18 Impact factor: 44.544

6. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Authors: Franck Morschhauser; John Radford; Achiel Van Hoof; Umberto Vitolo; Pierre Soubeyran; Herve Tilly; Peter C Huijgens; Arne Kolstad; Francesco d'Amore; Marcos Gonzalez Diaz; Mario Petrini; Catherine Sebban; Pier Luigi Zinzani; Marinus H J van Oers; Wim van Putten; Angelika Bischof-Delaloye; Ama Rohatiner; Gilles Salles; Jens Kuhlmann; Anton Hagenbeek
Journal: J Clin Oncol Date: 2008-10-14 Impact factor: 44.544

7. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

Authors: Michele Ghielmini; Shu-Fang Hsu Schmitz; Sergio B Cogliatti; Gabriella Pichert; Jörg Hummerjohann; Ursula Waltzer; Martin F Fey; Daniel C Betticher; Giovanni Martinelli; Fedro Peccatori; Urs Hess; Emanuele Zucca; Roger Stupp; Tibor Kovacsovics; Claudine Helg; Andreas Lohri; Mario Bargetzi; Daniel Vorobiof; Thomas Cerny
Journal: Blood Date: 2004-02-19 Impact factor: 22.113

Review 8. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

Authors: Liat Vidal; Anat Gafter-Gvili; Leonard Leibovici; Martin Dreyling; Michele Ghielmini; Shu-Fang Hsu Schmitz; Amos Cohen; Ofer Shpilberg
Journal: J Natl Cancer Inst Date: 2009-02-10 Impact factor: 13.506

9. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.

Authors: John D Hainsworth; Sharlene Litchy; John H Barton; Gerry Ann Houston; Robert C Hermann; James E Bradof; F Anthony Greco
Journal: J Clin Oncol Date: 2003-05-01 Impact factor: 44.544

10. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.

Authors: Howard Hochster; Edie Weller; Randy D Gascoyne; Thomas M Habermann; Leo I Gordon; Theresa Ryan; Lijun Zhang; Natalia Colocci; Stanley Frankel; Sandra J Horning
Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544

10 in total

1 in total

1. Rituximab maintenance for follicular lymphoma.

Authors: Liat Vidal; Anat Gafter-Gvili; Ofer Shpilberg
Journal: Nat Rev Clin Oncol Date: 2010-03 Impact factor: 66.675

1 in total